Drugmaker GSK to build $1.2bn US factory

Image: REUTERS/Dado Ruvic/Illustration/File Photo

The London-based firm made the announcement as part of a wider $30 billion investment in US research and development and supply chain infrastructure over five years, as President Donald Trump arrived in Britain for a state visit.

The factory in Pennsylvania will produce new medicines for respiratory diseases and cancer. Construction is set to start in 2026.

The company will also invest in digital technology, new drug substance manufacturing, and improved device assembly at GSK’s five US sites.

Its decision to expand its US footprint follows threats by Trump to impose import tariffs on the industry and seeks to boost domestic manufacturing.

“This landmark investment will create tens of thousands of American jobs and ensure that critical medicines and technologies are developed and manufactured right here on U.S. soil—where they belong,” US Commerce Secretary Howard Lutnick said in a statement shared by GSK.

British Prime Minister Keir Starmer said in the statement that the investment was a “powerful example of how UK-U.S. collaboration was driving real-world impact – improving people’s health, creating opportunity, and turbocharging growth.”